Opendata, web and dolomites
Horizon2020 projects coordinated by "ACADEMISCH ZIEKENHUIS LEIDEN"
| # | ||||
|---|---|---|---|---|
| 1 | RETHRIM Restoring tissue regeneration in patients with visceral Graft versus Host Disease. | 2015 | 5˙857˙587.00 | 5˙857˙587.00 |
| 2 | CIRCADOPAMINE The Role of Dopamine in the Regulation of Sleep and Circadian Rhythms | 2015 | 177˙598.00 | 177˙598.00 |
| 3 | GLYCOCAN Exploiting Glycosylation of Colorectal Cancer for the development of improved diagnostics and therapeutics | 2015 | 3˙297˙697.00 | 3˙293˙890.00 |
| 4 | BRIDGES Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES) | 2015 | 6˙460˙000.00 | 6˙200˙000.00 |
| 5 | FRESH AIR Free Respiratory Evaluation and Smoke-exposure reductionby primary Health cAre Integrated gRoups | 2015 | 2˙990˙750.00 | 2˙990˙750.00 |
| 6 | NOMA-MRI Novel materials to improve magnetic resonance imaging | 2015 | 2˙263˙692.00 | 2˙263˙692.00 |
| 7 | STEMCARDIORISK Stem Cells for Cardiac Arrhythmia Risk Assessment | 2015 | 1˙500˙000.00 | 1˙500˙000.00 |
| 8 | THYRAGE Resetting the THYRoid axis for prevention of AGE-related diseases and co-morbidities | 2016 | 6˙000˙001.00 | 6˙000˙000.00 |
| 9 | U-PGX Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen | 2016 | 14˙936˙613.00 | 14˙936˙613.00 |
| 10 | MY NERVE Translation of a fluorescent MYelin specific peripheral NERVE tracer | 2016 | 140˙000.00 | 140˙000.00 |
| 11 | ERCOPE The ER located master regulation of endosomal positioning and further movements | 2016 | 2˙383˙625.00 | 2˙383˙625.00 |
| 12 | GLYSIGN Exploitation of Glycosylation Signatures for Precision Medicine | 2016 | 1˙552˙846.00 | 1˙552˙846.00 |
| 13 | TIMASCAN Recirculated tissue macrophages (TiMa) in blood: Novel approach to early diagnosis and treatment monitoring in oncology | 2016 | 2˙500˙000.00 | 2˙500˙000.00 |
| 14 | BIO-ICD Biological auto-detection and termination of heart rhythm disturbances | 2017 | 1˙485˙028.00 | 1˙485˙028.00 |
| 15 | OVO-GROWTH Oogenesis spotlighted: making mature human oocytes | 2017 | 2˙000˙000.00 | 2˙000˙000.00 |
| 16 | AUTOCOMPLEMENT The role of complement in the induction of autoimmunity against post-translationally modified proteins | 2017 | 1˙999˙802.00 | 1˙999˙802.00 |
| 17 | ORCHID Organ on Chip in Development | 2017 | 520˙472.00 | 520˙472.00 |
| 18 | RACE Rheumatoid Arthritis Caught Early: investigating biological mechanisms preceding chronification of joint inflammation to identify patients prior to presentation of classic chronic arthritis | 2017 | 1˙500˙000.00 | 1˙500˙000.00 |
| 19 | BIONANOPATTERN Protein nano-patterning using DNA nanotechnology; control of surface-based immune system activation | 2018 | 1˙499˙850.00 | 1˙499˙850.00 |
| 20 | RECOMB Stem-cell based gene therapy for recombination deficient SCID (RECOMB) | 2018 | 5˙990˙460.00 | 5˙990˙460.00 |
| 21 | EPICBIOME Development of an innovative Airway-on-Chip microbiome cell culture model to investigate host-microbiome interactions at the airway epithelial surface | 2018 | 162˙864.00 | 162˙864.00 |
| 22 | DUX4 Function of DUX4 in skeletal muscle and non-muscle tissues | 2018 | 177˙598.00 | 177˙598.00 |
| 23 | MTBHLAE Investigation of a novel immune cell type in Tuberculosis: characterization of the specificity, function and pathogen killing ability of T cells restricted by non-classical HLA-E molecules | 2018 | 165˙598.00 | 165˙598.00 |
| 24 | EMBRACE Elucidating Mechanisms of Bladder Cancer Metastasis | 2018 | 177˙598.00 | 177˙598.00 |
| 25 | AUTO NERVE Tracers for targeting nerves in the autonomic nervous system | 2018 | 140˙000.00 | 140˙000.00 |
| 26 | CONT-END Attempts to Control the End of Life in People with Dementia: Two-level Approach to Examine Controversies | 2018 | 1˙988˙972.00 | 1˙988˙972.00 |
| 27 | ARTHRITISHEAL Establishing the molecular fundamentals of arthritic diseases – a step forward to Heal Arthritis | 2019 | 3˙297˙271.00 | 3˙297˙271.00 |
| 28 | HARMONIZATFORMS Defining the antithrombin measurand: role of proteoforms in harmonisation of diagnostic tests in thrombosis | 2019 | 187˙572.00 | 187˙572.00 |
| 29 | RESPIRINTM Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs | 2019 | 8˙060˙640.00 | 5˙687˙983.00 |
| 30 | RESPIRITB Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors | 2019 | 9˙962˙900.00 | 6˙840˙000.00 |
| 31 | TACTIC TArgeTed molecular Imaging and surgery for gastro-intestinal Cancer | 2019 | 150˙000.00 | 150˙000.00 |
| 32 | DIURNALHEALTH The circadian clock in day-active species: preserving our health in modern society | 2019 | 2˙233˙250.00 | 2˙233˙250.00 |
| 33 | CAST Active Monitoring of Cancer As An Alternative To Surgery | 2019 | 4˙111˙553.00 | 4˙111˙553.00 |
| 34 | RARITY RAtional design of canceR ImmunoTherapY: one size does not fit all | 2019 | 1˙499˙795.00 | 1˙499˙795.00 |
| 35 | NOVA-MRI Novel Applications in 19F Magnetic Resonance Imaging | 2020 | 4˙051˙634.00 | 4˙051˙634.00 |
| 36 | SIGNATURE Selection of human iPSC-derived cardiomyocytes by sinGle cell geNe expression and pAtch clamp for a maTUre caRdiac modEl | 2020 | 187˙572.00 | 187˙572.00 |
| 37 | RISE-WELL Critical solutions for elderly well-being | 2020 | 2˙691˙279.00 | 2˙691˙279.00 |
| 38 | ACQUIRE Assessing cardiac Contractility and Quantification of Underlying mechanisms In vitro via Response in Excitation-contraction coupling | 2020 | 0.00 | 150˙000.00 |
More Horizon 2020 projects
The Institution ACADEMISCH ZIEKENHUIS LEIDEN has been involved also in the following Horizon 2020 projects.
- NEPHSTROM (2015, participant)
- CDS-QUAMRI (2015, participant)
- ANTIVIRALS (2015, participant)
- TBVAC2020 (2015, participant)
- ARISE (2015, participant)
- MYAIRCOACH (2015, participant)
- PRISAR (2015, participant)
- EUROSTEMCELL (2015, participant)
- INEXT (2015, participant)
- MELGEN (2015, participant)
- MOGLYNET (2015, participant)
- ISPIC (2016, participant)
- EVAG (2015, participant)
- EU-TOXRISK (2016, participant)
- BOOSTB4 (2016, participant)
- BETACELLTHERAPY (2015, participant)
- SCIDNET (2016, participant)
- UM CURE 2020 (2016, participant)
- TECHNOBEAT (2016, participant)
- ADOPT BBMRI-ERIC (2015, participant)
- POWER2DM (2016, participant)
- ARREST BLINDNESS (2016, participant)
- SMARTOOL (2016, participant)
- SURGASSIST (2016, participant)
- LEADING FELLOWS (2017, partner)
- ASTONISH (2016, participant)
- HBP SGA1 (2016, participant)
- EN_ACTI2NG (2017, participant)
- DNAREPAIRMAN (2017, participant)
- OPTIMALVAX (2017, participant)
- ZIKALLIANCE (2016, participant)
- CHARMED (2017, participant)
- HISTO-MRI (2017, participant)
- EOSCPILOT (2017, participant)
- IMFORFUTURE (2017, participant)
- VSV-EBOVAC (2015, participant)
- RHAPSODY (2016, participant)
- PERISCOPE (2016, participant)
- PRISM (2016, participant)
- ROADMAP (2016, participant)
- INNODIA (2015, participant)
- VSV-EBOPLUS (2016, participant)
- IMGENE (2017, participant)
- TRANSVAC2 (2017, participant)
- TUMOR-TREG-TARGETING (2018, partner)
- UBICODE (2018, participant)
- A4B (2017, participant)
- RTCURE (2017, participant)
- COMBACTE-CDI (2017, participant)
- GEROPROTECT (2017, participant)
- TRACE (2018, participant)
- CANCER (2018, participant)
- SORAPRAZAN (2017, participant)
- ACORN (2018, participant)
- TRIM-NET (2019, participant)
- EUROOC (2018, participant)
- RENALTOOLBOX (2018, participant)
- EOSC-LIFE (2019, participant)
- IM2PACT (2019, participant)
- EU-OPENSCREEN-DRIVE (2019, participant)
- HBP SGA2 (2018, participant)
- ICEI (2018, participant)
- EJP RD (2019, participant)
- MICROB-PREDICT (2019, participant)
- BIOMAP (2019, participant)
- VASA (2019, participant)
- INITIATE (2019, participant)
- SIMICA (2019, participant)
- TRAINCKDIS (2020, participant)
- PAVE (2019, participant)
- PRISAR2 (2020, participant)
- AUTOCRAT (2020, participant)
- SMA-TB (2020, participant)
- BIND (2020, participant)
- GC_1000 (2020, participant)
- ESPACE (2020, participant)
- ISLET (2020, participant)
- IDEA-FAST (2019, participant)
- SENATOR (2020, participant)
- INCENTIVE (2020, participant)